{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T20:44:32Z","timestamp":1777322672594,"version":"3.51.4"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["RE\/18\/6\/34217"],"award-info":[{"award-number":["RE\/18\/6\/34217"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vera Melrose Heart Failure Research Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and aims<\/jats:title>\n                  <jats:p>Randomized controlled trials (RCTs) have assessed the effects of renin\u2013angiotensin system (RAS) blockers in adults with coronavirus disease 2019 (COVID-19). This meta-analysis provides estimates of the safety and efficacy of treatment with (vs. without) RAS blockers from these trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>PubMed, Web of Science, and ClinicalTrials.gov were searched (1 March\u201312 April 2023). Event\/patient numbers were extracted, comparing angiotensin-converting enzyme (ACE) inhibitor\/angiotensin-receptor blocker (ARB) treatment with no treatment, for the outcomes: intensive care unit (ICU) admission, mechanical ventilation, vasopressor use, acute kidney injury (AKI), renal replacement therapy (RRT), acute myocardial infarction, stroke\/transient ischaemic attack, heart failure, thromboembolic events, and all-cause death. Fixed-effects meta-analysis estimates were pooled.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Sixteen RCTs including 3492 patients were analysed. Compared with discontinuation of RAS blockers, continuation was not associated with increased risk of ICU [risk ratio (RR) 0.96, 0.66\u20131.41], ventilation (RR 0.77, 0.55\u20131.09), vasopressors (RR 0.92, 0.58\u20131.44), AKI (RR 1.01, 0.40\u20132.56), RRT (RR 1.01, 0.46\u20132.21), or thromboembolic events (RR 1.07, 0.36\u20133.19). RAS blocker initiation was not associated with increased risk of ICU (RR 0.71, 0.47\u20131.08), ventilation (RR 1.12, 0.91\u20131.38), AKI (RR 1.28, 0.89\u20131.86), RRT (RR 1.66, 0.89\u20133.12), or thromboembolic events (RR 1.20, 0.06\u201323.70), although vasopressor use increased (RR 1.27, 1.02\u20131.57). The RR for all-cause death in the continuation\/discontinuation trials was 1.24 (0.80\u20131.92), and 1.22 (0.96\u20131.55) in the initiation trials. In patients with severe\/critical COVID-19, RAS blocker initiation increased the risk of all-cause death (RR 1.31, 1.01\u20131.72).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>ACE inhibitors and ARBs may be continued in non-severe COVID-19 infection, where indicated. Conversely, initiation of RAS blockers may be harmful in critically ill patients.<\/jats:p>\n                  <jats:p>PROSPERO registration number: CRD42023408926.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvad067","type":"journal-article","created":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T04:44:51Z","timestamp":1695444291000},"page":"68-80","source":"Crossref","is-referenced-by-count":12,"title":["Effects of renin\u2013angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9213-2067","authenticated-orcid":false,"given":"Matthew M Y","family":"Lee","sequence":"first","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow, G12 8TA , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6853-7574","authenticated-orcid":false,"given":"Toru","family":"Kondo","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow, G12 8TA , UK"},{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine , Nagoya , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0050-2129","authenticated-orcid":false,"given":"Ross T","family":"Campbell","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow, G12 8TA , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6333-9496","authenticated-orcid":false,"given":"Mark C","family":"Petrie","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow, G12 8TA , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1604-2593","authenticated-orcid":false,"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow, G12 8TA , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott D","family":"Solomon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School , Boston, MA 02115 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0885-1953","authenticated-orcid":false,"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School , Boston, MA 02115 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4306-5317","authenticated-orcid":false,"given":"Pardeep S","family":"Jhund","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow, G12 8TA , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6317-3975","authenticated-orcid":false,"given":"John J V","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow, G12 8TA , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,9,22]]},"reference":[{"key":"2024010504420540500_bib1","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin\u2013angiotensin\u2013aldosterone system inhibitors in patients with Covid-19","volume":"382","author":"Vaduganathan","year":"2020","journal-title":"N Engl J Med"},{"key":"2024010504420540500_bib2","doi-asserted-by":"crossref","first-page":"e072175","DOI":"10.1136\/bmj-2022-072175","article-title":"Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial","volume":"379","author":"Jardine","year":"2022","journal-title":"BMJ"},{"key":"2024010504420540500_bib3","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1001\/jama.2020.25864","article-title":"Effect of discontinuing vs. continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial","volume":"325","author":"Lopes","year":"2021","journal-title":"JAMA"},{"key":"2024010504420540500_bib4","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S2213-2600(21)00214-9","article-title":"Discontinuation versus continuation of renin\u2013angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial","volume":"9","author":"Bauer","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024010504420540500_bib5","doi-asserted-by":"crossref","first-page":"e222735","DOI":"10.1001\/jamanetworkopen.2022.2735","article-title":"Efficacy of losartan in hospitalized patients with COVID-19-induced lung injury: a randomized clinical trial","volume":"5","author":"Puskarich","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2024010504420540500_bib6","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1001\/jama.2023.4480","article-title":"Effect of angiotensin-converting enzyme inhibitor and angiotensin-receptor blocker initiation on organ support\u2014free days in patients hospitalized with COVID-19: a randomized clinical trial","volume":"329","author":"Writing Committee for the REMAP-CAP Investigators","year":"2023","journal-title":"JAMA"},{"key":"2024010504420540500_bib7","doi-asserted-by":"crossref","first-page":"e14124","DOI":"10.1111\/ijcp.14124","article-title":"Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: a randomised clinical trial","volume":"75","author":"Nouri-Vaskeh","year":"2021","journal-title":"Int J Clin Pract"},{"key":"2024010504420540500_bib8","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ahj.2020.05.010","article-title":"Rationale and design of the PRAETORIAN-COVID trial: a double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease","volume":"226","author":"Gommans DHF, Nas J, Pinto-Sietsma SJ, Koop Y, Konst RE, Mensink F, Aarts GWA, Konijnenberg LSF, Cortenbach K, Verhaert DVM, Thannhauser J, Mol JQ, Rooijakkers MJP, Vos JL, van Rumund A, Vart P, Hassing RJ, Cornel JH, de Jager CPC, van den Heuvel MM, van der Hoeven HG, Verbon A, Pinto YM, van Royen N, van Kimmenade RRJ; Event committee; de Leeuw PW, van Agtmael MA, Bresser P; Data Safety Monitoring Board; van Gilst WH, Vonk-Noordergraaf A, Tijssen JGP; Steering committee; van Royen N, de Jager CPC, van den Heuvel MM, van der Hoeven HG, Verbon A, Pinto YM, van Kimmenade RRJ","year":"2020","journal-title":"Am Heart J"},{"key":"2024010504420540500_bib9","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ahj.2022.01.015","article-title":"A randomized controlled trial of renin\u2013angiotensin\u2013aldosterone system inhibitor management in patients admitted in hospital with COVID-19","volume":"247","author":"Sharma","year":"2022","journal-title":"Am Heart J"},{"key":"2024010504420540500_bib10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-2600(20)30558-0","article-title":"Continuation versus discontinuation of renin\u2013angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial","volume":"9","author":"Cohen","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024010504420540500_bib11","article-title":"Telmisartan in respiratory failure due to COVID-19 (STAR-COVID)","author":"Gracia-Ramos","year":"2020"},{"key":"2024010504420540500_bib12","article-title":"Switch of renin\u2013angiotensin system inhibitors in patients with Covid-19 (SWITCH-COVID)","author":"Caramelli","year":"2021"},{"key":"2024010504420540500_bib13","doi-asserted-by":"crossref","first-page":"100957","DOI":"10.1016\/j.eclinm.2021.100957","article-title":"A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19","volume":"37","author":"Puskarich","year":"2021","journal-title":"eClinicalMedicine"},{"key":"2024010504420540500_bib14","doi-asserted-by":"crossref","first-page":"100968","DOI":"10.1016\/j.conctc.2022.100968","article-title":"COVIDMED\u2014an early pandemic randomized clinical trial of losartan treatment for hospitalized COVID-19 patients","volume":"29","author":"Freilich","year":"2022","journal-title":"Contemp Clin Trials Commun"},{"key":"2024010504420540500_bib15","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1093\/ajh\/hpab111","article-title":"Effects of renin\u2013angiotensin\u2013aldosterone inhibitors on early outcomes of hypertensive COVID-19 patients: a randomized triple-blind clinical trial","volume":"34","author":"Najmeddin","year":"2021","journal-title":"Am J Hypertens"},{"key":"2024010504420540500_bib16","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s40121-021-00453-3","article-title":"Randomized prospective open label study shows no impact on clinical outcome of adding losartan to hospitalized COVID-19 patients with mild hypoxemia","volume":"10","author":"Geriak","year":"2021","journal-title":"Infect Dis Ther"},{"key":"2024010504420540500_bib17","doi-asserted-by":"crossref","first-page":"100962","DOI":"10.1016\/j.eclinm.2021.100962","article-title":"Telmisartan for treatment of Covid-19 patients: an open multicenter randomized clinical trial","volume":"37","author":"Duarte","year":"2021","journal-title":"eClinicalMedicine"},{"key":"2024010504420540500_bib18","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jacc.2020.05.040","article-title":"Ramipril in high-risk patients with COVID-19","volume":"76","author":"Amat-Santos","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2024010504420540500_bib19","doi-asserted-by":"crossref","first-page":"e026143","DOI":"10.1161\/JAHA.122.026143","article-title":"Renin\u2013angiotensin system inhibitors in patients with COVID-19: a meta-analysis of randomized controlled trials led by the International Society of Hypertension","volume":"11","author":"Gnanenthiran","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2024010504420540500_bib20","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2024010504420540500_bib21","doi-asserted-by":"crossref","first-page":"100491","DOI":"10.1016\/j.xkme.2022.100491","article-title":"Sick day medication guidance for people with diabetes, kidney disease, or cardiovascular disease: a systematic scoping review","volume":"4","author":"Watson","year":"2022","journal-title":"Kidney Med"},{"key":"2024010504420540500_bib22","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1161\/HYPERTENSIONAHA.120.15178","article-title":"Chronic use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers is high among intensive care unit patients with non-COVID-19 sepsis but carries a moderately increased risk of death","volume":"75","author":"Sunden-Cullberg","year":"2020","journal-title":"Hypertension"},{"key":"2024010504420540500_bib23","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1097\/CCM.0000000000003654","article-title":"Effect of antihypertensive medications on sepsis-related outcomes: a population-based cohort study","volume":"47","author":"Kim","year":"2019","journal-title":"Crit Care Med"},{"key":"2024010504420540500_bib24","doi-asserted-by":"crossref","first-page":"e4260","DOI":"10.1136\/bmj.e4260","article-title":"Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin-receptor blockers: systematic review and meta-analysis","volume":"345","author":"Caldeira","year":"2012","journal-title":"BMJ"},{"key":"2024010504420540500_bib25","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.matt.2021.09.022","article-title":"Inhaled ACE2-engineered microfluidic microsphere for intratracheal neutralization of COVID-19 and calming of the cytokine storm","volume":"5","author":"Wang","year":"2022","journal-title":"Matter"},{"key":"2024010504420540500_bib26","doi-asserted-by":"crossref","first-page":"151957","DOI":"10.1016\/j.imbio.2020.151957","article-title":"Treatment with inhaled formulation of angiotensin-(1-7) reverses inflammation and pulmonary remodeling in a model of chronic asthma","volume":"225","author":"Magalh\u00e3es","year":"2020","journal-title":"Immunobiology"},{"key":"2024010504420540500_bib27","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1001\/jama.2023.3546","article-title":"ACTIV-4 host tissue investigators. renin-angiotensin system modulation with synthetic angiotensin (1-7) and angiotensin II type 1 receptor-biased ligand in adults with Covid-19: two randomized clinical trials","volume":"329","author":"Self","year":"2023","journal-title":"JAMA"},{"key":"2024010504420540500_bib28","article-title":"Ramipril for the treatment of COVID-19 (RAMIC)","year":"2020"},{"key":"2024010504420540500_bib29","article-title":"Evaluation of the potential benefit of renin\u2013angiotensin system inhibitors (RASi, ACEi\/ARB) in high-risk patients with COVID-19. The COVID-RASi trial","year":"2020"},{"key":"2024010504420540500_bib30","article-title":"Host response mediators in coronavirus (COVID-19) infection\u2014is there a protective effect of losartan and other ARBs on outcomes of coronavirus infection? (ARBs CORONA II)","year":"2020"},{"key":"2024010504420540500_bib31","article-title":"Coronavirus (COVID-19) ACEi\/ARB investigation (CORONACION)","year":"2020"},{"key":"2024010504420540500_bib32","article-title":"Early treatment of vulnerable individuals with non-severe SARS-CoV-2 infection (COVERAGE-A)","year":"2021"},{"key":"2024010504420540500_bib33","article-title":"Controlled trial of angiotensin-receptor blocker (ARB) & chemokine receptor type 2 (CCR2) antagonist for the treatment of COVID-19 (CLARITY 2)","year":"2021"},{"key":"2024010504420540500_bib34","doi-asserted-by":"crossref","first-page":"d4829","DOI":"10.1136\/bmj.d4829","article-title":"Multiplicity of data in trial reports and the reliability of meta-analyses: empirical study","volume":"343","author":"Tendal","year":"2011","journal-title":"BMJ"},{"key":"2024010504420540500_bib35","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/ehjcvp\/pvaa138","article-title":"Renin\u2013angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis","volume":"8","author":"Lee","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024010504420540500_bib36","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/14779072.2023.2184351","article-title":"Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in hospitalized patients with COVID-19: an updated systematic review and meta-analysis of randomized clinical trials","volume":"21","author":"Paguio","year":"2023","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"2024010504420540500_bib37","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/ajh\/hpac001","article-title":"Effects of renin\u2013angiotensin system inhibitors on mortality and disease severity of COVID-19 patients: a meta-analysis of randomized controlled trials","volume":"35","author":"Yin","year":"2022","journal-title":"Am J Hypertens"},{"key":"2024010504420540500_bib38","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jointm.2022.05.004","article-title":"The effect of renin\u2013angiotensin\u2013aldosterone system inhibitors in patients with hypertension and COVID-19: a meta-analysis of randomized controlled trials and propensity score-matched studies","volume":"2","author":"Zhang","year":"2022","journal-title":"J Intensive Med"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvad067\/52248742\/pvad067.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/1\/68\/55013882\/pvad067.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/1\/68\/55013882\/pvad067.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T05:07:11Z","timestamp":1704431231000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/10\/1\/68\/7280755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,22]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,9,22]]},"published-print":{"date-parts":[[2024,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvad067","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2023,9,22]]}}}